Compare Amphastar Pharmaceuticals Inc (AMPH) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs McCormick & Company, Incorporated — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while McCormick & Company, Incorporated trades at $53.03 (market cap $14.27B). The key difference: McCormick & Company, Incorporated is far larger — about 16.5× Amphastar Pharmaceuticals Inc's market cap, and McCormick & Company, Incorporated pays a 3.61% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MKC | |
|---|---|---|
Market Cap | $863.95M | $14.27B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $72.26 |
52-Week Low | $16.87 | $45.60 |
Enterprise Value | $1.26B | $18.87B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
MKC trades at $52.96, up 1.3% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67 suggesting 13% upside. The company reported Q2 2026 results that beat expectations, driven by the McCormick de Mexico acquisition and margin expansion, with revenue growth of 16.7% year-over-year. The pending $65 billion merger with Unilever's food business represents a transformative opportunity, though integration risks remain.
The outlook is positive, supported by strong profitability metrics, including a 21.91% net income margin and 25.7% ROE, alongside a reasonable valuation with a P/E of 8.81. Key risks include execution of the Unilever deal, competitive pressures in the consumer segment, and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
